By Momo Yamamoto, Senior Investor Research Analyst, LSN
Life Science Nation (LSN) is heading back to Yokohama this October for BioJapan 2026, taking place on October 7-9, 2026 at PACIFICO Yokohama. As one of Asia’s leading partnering events for the life sciences industry, BioJapan provides an important platform for startups, investors, pharmaceutical companies, strategic partners, and ecosystem stakeholders from around the world to connect and explore new opportunities. This year, LSN is pleased to participate in the conference and in two seminars focused on helping life science companies better understand and access international funding and partnership opportunities.
LSN Founder & CEO, Dennis Ford, will join KBIC (Kobe Biomedical Innovation Cluster) and MEDISO (Medical Innovation Support Office) on October 8, 2026 from 1 PM – 2PM JST at the Japan Healthcare Venture Summit (JHVS), held alongside BioJapan. The session titled “Key Points for Early-Phase Global Fundraising” will introduce government initiatives and programs designed to help early-stage ventures expand internationally and connect with overseas investors. We will join representatives from the Ministry of Economy, Trade, and Industry (METI), JIC Venture Growth Investments, VC Cell Therapy, United Immunity, CellFold, KBIC, and Mitsubishi Research Institute for a discussion on global fundraising and international growth.
On October 9, 2026 from 11:30 AM – 12:30 PM JST, LSN will be hosting a seminar with KBIC titled: “Inside Global Fundraising: LSN Framework for Startup Readiness and Global Capital Raising Success”. KBIC is Japan’s largest biocluster, hosting more than 340 organizations to accelerate innovation in the region. For life science companies seeking international expansion, global fundraising has become an important strategy for accelerating R&D and commercialization. During this seminar, LSN will introduce latest trends in global fundraising and practical strategies for investor engagement, drawing on LSN’s experience working with thousands of life science companies and investors worldwide. This discussion will feature: Haruhiko Koike (KBIC), Keiko Kobayashi (KBIC), Dennis Ford (LSN), and Claire Jeong (LSN).
This seminar will also highlight the upcoming RESI Asia, taking place in Tokyo at the APA InterContinental on April 13, 2027. As part of LSN’s globally recognized RESI Conference Series, RESI Asia will provide Japanese and Asian startups with opportunities to connect directly with international investors and explore new pathways for global growth.
LSN’s participation at BioJapan reflects its continued commitment to supporting the Japanese life science ecosystem as they seek to expand beyond the domestic market. We look forward to returning to the conference next week!
